Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review

被引：0
|
作者：
Zohreh Maghsoomi
Zahra Emami
Ramin Malboosbaf
Mojtaba Malek
Mohammad E. Khamseh
机构：
[1] Iran University of Medical Science (IUMS),Endocrine Research Center, Institute of Endocrinology and Metabolism
[2] Iran University of Medical Sciences (IUMS),Research Center for Prevention of Cardiovascular Disease, Institute of Endocrinology and Metabolism
来源：
BMC Cancer | / 21卷
关键词：
Peptide receptor radionuclide therapy; Radioiodine refractory-differentiated thyroid Cancer; Medullary thyroid carcinoma; Papillary thyroid carcinoma; Yttrium-90; 177Lu-DOTATATE; Indium-111; Systematic review;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] 68Ga-PSMA uptake in a radioiodine-refractory metastatic differentiated thyroid cancer patient
    Alcin, G.
    Arslan, E.
    Aksoy, T.
    Cermik, T. F.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2022, 41 : S42 - S43
  • [32] TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer
    Yang, Xue
    Li, Jiao
    Li, Xiaoyi
    Liang, Zhiyong
    Gao, Wen
    Liang, Jun
    Cheng, Shujun
    Lin, Yansong
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (02) : 258 - 265
  • [33] Radioiodine-refractory differentiated thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine resistance
    Shen, Huize
    Zhu, Rui
    Liu, Yanyang
    Hong, Yangjian
    Ge, Jiaming
    Xuan, Jie
    Niu, Wenyuan
    Yu, Xuefei
    Qin, Jiang-Jiang
    Li, Qinglin
    DRUG RESISTANCE UPDATES, 2024, 72
  • [34] Sorafenib and radioiodine-refractory differentiated thyroid cancer (RR-DTC): a systematic review and meta-analysis
    Feng, Guoli
    Luo, Yi
    Zhang, Qi
    Zeng, Feng
    Xu, Jie
    Zhu, Jingqiang
    ENDOCRINE, 2020, 68 (01) : 56 - 63
  • [35] Sorafenib and radioiodine-refractory differentiated thyroid cancer (RR-DTC): a systematic review and meta-analysis
    Guoli Feng
    Yi Luo
    Qi Zhang
    Feng Zeng
    Jie Xu
    Jingqiang Zhu
    Endocrine, 2020, 68 : 56 - 63
  • [36] FAP-Targeted Radionuclide Therapy of Advanced Radioiodine-Refractory Differentiated Thyroid Cancer With Multiple Cycles of 177Lu-FAPI-46
    Fu, Hao
    Huang, Jingxiong
    Sun, Long
    Wu, Hua
    Chen, Haojun
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (10) : 906 - 907
  • [37] Efficacy and safety of multi-kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer: a systematic review and meta-analysis of clinical trials
    Su, Jingyang
    Wang, Menglei
    Fu, Yue
    Yan, Jiang
    Shen, Yuezhong
    Jiang, Jing
    Wang, Jue
    Lu, Jinhua
    Zhong, Yazhen
    Lin, Xianlei
    Lin, Zechen
    Lin, Shengyou
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (09) : 999 - 1008
  • [38] Radioiodine-refractory thyroid cancer: a complex challenge
    Vitale, Giovanni
    Pellegrino, Giuseppe
    Desiderio, Elio
    Barrea, Luigi
    MINERVA MEDICA, 2021, 112 (06) : 686 - 688
  • [39] Radioiodine refractory differentiated thyroid cancer
    Jin, Yuchen
    Van Nostrand, Douglas
    Cheng, Lingxiao
    Liu, Min
    Chen, Libo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 125 : 111 - 120
  • [40] Radioiodine refractory differentiated thyroid cancer
    Boudina, Maria
    HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2023, 26 : 65 - 68
12345